Notice

As a result of the current Federal government funding situation, the information on this website may not be up to date or acted upon.  

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at https://www.opm.gov/.

Gordon Whiteley, Ph.D.

Director, CPTAC Antibody Characterization Laboratory, Frederick National Laboratory for Cancer Research

Gordon Whiteley

Dr. Whiteley spent more than 30 years in the medical diagnostics industry directing conception, development and FDA filing of more than 75 diagnostic tests and accompanying instrumentation.  This included 510(k), PMA and licensed biological filings for a variety of infectious diseases, cancer biomarkers, steroid and hormone, therapeutic drugs and cardiac markers.  Prior to that, Dr. Whiteley directed the clinical lab service in microbiology for MDS Health Group Ltd. In Toronto.  Dr. Whiteley joined Leidos Biomedical Research (formerly SAIC) in 2001 to evaluate mass spectrometry as a possible diagnostic test platform.  Since 2008, Dr. Whiteley has directed the Antibody Characterization Lab for the Office of Cancer Clinical Proteomics Research.  Dr. Whiteley graduated from the University of Toronto with a Ph.D. in microbiology.